Severity of cytokine release syndrome and neurotoxicity. (A) Severity of CRS in treated patients as a function of cell dose, disease burden, CD19 burden, and lymphodepletion regimen. (B) Severity of neurotoxicity based on parameters described in (A) as well as severity of CRS.